The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide

Alzheimer’s disease (AD) is characterized by brain plaques containing the beta-amyloid peptide (Aβ). One approach for treating AD is by blocking Aβ aggregation. Activity-dependant neuroprotective protein contains a peptide, NAP that protects neurons in culture against Aβ toxicity. Here, NAP was show...

Full description

Saved in:
Bibliographic Details
Published inPeptides (New York, N.Y. : 1980) Vol. 24; no. 9; pp. 1413 - 1423
Main Authors Ashur-Fabian, Osnat, Segal-Ruder, Yael, Skutelsky, Ehud, Brenneman, Douglas E., Steingart, Ruth A., Giladi, Eliezer, Gozes, Illana
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.09.2003
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Alzheimer’s disease (AD) is characterized by brain plaques containing the beta-amyloid peptide (Aβ). One approach for treating AD is by blocking Aβ aggregation. Activity-dependant neuroprotective protein contains a peptide, NAP that protects neurons in culture against Aβ toxicity. Here, NAP was shown to inhibit Aβ aggregation using: (1) fluorimetry; (2) electron microscopy; (3) high-throughput screening of Aβ deposition onto a synthetic template (synthaloid); and (4) Congo Red staining of neurons. Further assays showed biotin–NAP binding to Aβ. These results suggest that part of the neuroprotective mechanism exerted by NAP is through modulation of toxic protein folding in the extracellular milieu.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0196-9781
1873-5169
DOI:10.1016/j.peptides.2003.08.005